Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Arvinas Inc
ARVN | US
13.37
USD-0.23
-1.69%
ARVN | US
Loading StockChartView...
About Arvinas Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
13.37
Open
13.21
High
13.79
Low
13.07
Arvinas Inc. a clinical-stage biotechnology company engages in the discovery development and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766 investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer which are in Phase 1/2 clinical trials; and ARV-471 an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc. Genentech Inc. F. Hoffman-La Roche Ltd. and Bayer AG. Arvinas Inc. was founded in 2013 and is based in New Haven Connecticut.
View LessARVN | US
Risk
56.0
Sharpe
-0.37
Luna's Score
51/100
Recommendation
Hold
Luna says (ARVN | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
40.8%1 month
56.0%3 months
48.2%6 months
57.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
17.70
Price to book
3.09
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-1.62
Ent. to rev.
6.75
PEG
-
Other Fundamentals
EBITDA
-366.20M
MarketCap
915.46M
MarketCap(USD)
915.46M
Div. yield
-
Op. margin
-63.40
Erngs. growth
-
Rev. growth
40.40
Ret. on equity
-60.80
Short ratio
24.36
Short perc.
15.83
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.98
Range1M
3.00
Range3M
3.14
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.68
Price X volume
7.90M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.62 | 0.53 | Cheaper |
| Ent. to Revenue | 6.75 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.09 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 48.21 | 72.80 | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 915.46M | 3.66B | Emerging |
